

Resource Summary Report

Generated by [dkNET](#) on Aug 31, 2026

National Cancer Institute

RRID:SCR_011176

Type: Tool

Proper Citation

National Cancer Institute (RRID:SCR_011176)

Resource Information

URL: <http://www.cancer.gov/researchandfunding>

Proper Citation: National Cancer Institute (RRID:SCR_011176)

Description: Federal government agency for cancer research and training established in 1937. National Cancer Program is responsibility of NCI to coordinate, conduct and support research, training, health information dissemination with respect to cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and continuing care of cancer patients and families of cancer patients. Supports construction of laboratories, clinics, and related facilities necessary for cancer research through award of grants.

Abbreviations: NCI

Resource Type: government granting agency, institution

Keywords: institute, federal, government, agency, cancer, research, training, program, health, diagnosis, prevention, treatment, clinic, laboratory, grant

Availability: <https://ror.org/040gcmg81>

Resource Name: National Cancer Institute

Resource ID: SCR_011176

Alternate IDs: , Wikidata Q664846, nlx_inv_1005051, GRID grid.48336.3a ISNI 0000 0004 1936 8075, nlx_inv_1005082, Crossref Funder ID 100000054, SCR_011403

Record Creation Time: 20220129T080302+0000

Record Last Update: 20260829T183103+0000

Ratings and Alerts

No rating or validation information has been found for National Cancer Institute.

No alerts have been found for National Cancer Institute.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 353 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Huang C, et al. (2026) Survival Genie 2: a next-generation web server for targeted and single-cell-based survival analyses. *Genome medicine*, 18(1).

Luo M, et al. (2025) Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations. *Cancer discovery*, 15(3), 511.

Jaswal AP, et al. (2025) Targeting Tumor-Infiltrating Immune Cells for Targeted Alpha Therapy in Gliomas: Optimization of [225Ac]Ac-DOTA- α CD11b Dosing through PET Imaging. *Molecular cancer therapeutics*, 24(12), 1948.

Heckman CJ, et al. (2025) Digital Skin Cancer Risk Reduction Interventions for Young Adults: Findings from a Hybrid Type-II Effectiveness-Implementation Trial. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 34(6), 962.

Yi X, et al. (2024) Tumor-associated antigen prediction using a single-sample gene expression state inference algorithm. *Cell reports methods*, 4(11), 100906.

Meernik C, et al. (2024) Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina. *Cancer research communications*, 4(11), 2968.

Ye T, et al. (2023) Microsatellite instability states serve as predictive biomarkers for tumors chemotherapy sensitivity. *iScience*, 26(7), 107045.

Schweighofer N, et al. (2023) Identification of Novel Intronic SNPs in Transporter Genes Associated with Metformin Side Effects. *Genes*, 14(8).

Sokale IO, et al. (2023) Racial/Ethnic Disparities in Cervical Cancer Stage at Diagnosis: Mediating Effects of Neighborhood-level Socioeconomic Deprivation. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 32(6), 818.

Hurtado-Navarro L, et al. (2023) NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. *Cell reports. Medicine*, 4(12), 101329.

Atakpa EC, et al. (2023) Development and evaluation of a method to assess breast cancer risk using a longitudinal history of mammographic density: a cohort study. *Breast cancer research : BCR*, 25(1), 147.

Schweighofer N, et al. (2020) Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes. *Diabetes, metabolic syndrome and obesity : targets and therapy*, 13, 2069.

, et al. (2014) Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. *Lancet (London, England)*, 383(9928), 1561.

Frantzi M, et al. (2014) Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. *Clinical and translational medicine*, 3(1), 7.

Hrdli?ková R, et al. (2014) Multiple tumor suppressor microRNAs regulate telomerase and TCF7, an important transcriptional regulator of the Wnt pathway. *PloS one*, 9(2), e86990.

Yang CS, et al. (2014) Recent scientific studies of a traditional chinese medicine, tea, on prevention of chronic diseases. *Journal of traditional and complementary medicine*, 4(1), 17.

Ferrari N, et al. (2014) Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. *PloS one*, 9(6), e100759.

Haverman TM, et al. (2014) Oral complications in hematopoietic stem cell recipients: the role of inflammation. *Mediators of inflammation*, 2014, 378281.

Lee S, et al. (2014) Loss of Dlg-1 in the mouse lens impairs fibroblast growth factor receptor signaling. *PloS one*, 9(5), e97470.

Vacchelli E, et al. (2014) Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. *Oncoimmunology*, 3(1), e27048.